- Home
- FTHM vs IGC Comparison
FTHM vs IGC Comparison
Compare FTHM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- IGC
- Stock Information
- Founded
- FTHM 2010
- IGC 2005
- Country
- FTHM United States
- IGC United States
- Employees
- FTHM N/A
- IGC N/A
- Industry
- FTHM Real Estate
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- IGC Health Care
- Exchange
- FTHM Nasdaq
- IGC Nasdaq
- Market Cap
- FTHM 33.6M
- IGC 20.2M
- IPO Year
- FTHM 2020
- IGC N/A
- Fundamental
- Price
- FTHM $1.41
- IGC $0.31
- Analyst Decision
- FTHM Buy
- IGC Strong Buy
- Analyst Count
- FTHM 1
- IGC 2
- Target Price
- FTHM $2.50
- IGC $3.88
- AVG Volume (30 Days)
- FTHM 75.3K
- IGC 232.1K
- Earning Date
- FTHM 08-11-2025
- IGC 08-07-2025
- Dividend Yield
- FTHM N/A
- IGC N/A
- EPS Growth
- FTHM N/A
- IGC N/A
- EPS
- FTHM N/A
- IGC N/A
- Revenue
- FTHM $357,816,000.00
- IGC $1,271,000.00
- Revenue This Year
- FTHM $32.40
- IGC $15.26
- Revenue Next Year
- FTHM $18.04
- IGC $3.41
- P/E Ratio
- FTHM N/A
- IGC N/A
- Revenue Growth
- FTHM 5.80
- IGC N/A
- 52 Week Low
- FTHM $0.65
- IGC $0.25
- 52 Week High
- FTHM $3.37
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- FTHM 65.20
- IGC 44.22
- Support Level
- FTHM $1.24
- IGC $0.30
- Resistance Level
- FTHM $1.36
- IGC $0.32
- Average True Range (ATR)
- FTHM 0.09
- IGC 0.01
- MACD
- FTHM 0.03
- IGC -0.00
- Stochastic Oscillator
- FTHM 88.46
- IGC 0.00
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.